

PUBLICATIONS – data from The Norwegian Renal Registry

- 260: Boenink R, Stel VS, Waldum-Grevbo BE, Collart F, Kerschbaum J, Heaf JG, de Meester J, Finne P, García-Marcos SA, Evans M, Ambühl PM, Arici M, Ayav C, Steenkamp C, Cases A, Traynor JP, Palsson R, Zoccali C, Massy ZA, Jager KJ, Kramer A. Data from the ERA-EDTA Registry were examined for trends in excess mortality in European adults on kidney replacement therapy. *Kidney Int* 2020; 98(4): 999-1008.
- 259: Jansz TT, Noordzij M, Kramer A, Laruelle E, Couchoud C, Collart F, Cases A, Arici M, Helve J, Waldum-Grevbo B, Rydell H, Traynor JP, Zoccali C, Massy ZA, Jager KJ, van Jaarsveld BC. Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry. *Nephrol Dial Transplant* 2020; 35(3): 488-495.
- 258: Gjerde A, Reisæter AV, Skrunes R, Marti H-P, Vikse BE. Intrauterine Growth Restriction and Risk of Diverse Forms of Kidney Disease during the First 50 Years of Life. *Clin J Am Soc Nephrol*. 2020; doi: 10.2215/CJN.04080320.
- 257: Gjerde A, Lillås BS, Marti H-P, Reisæter AV, Vikse BE. Intrauterine growth restriction, preterm birth and risk of end-stage renal disease during the first 50 years of life *Nephrol Dial Transplant*. 2020; 35(7): 1157-1163.
- 256: Bjerre A, Mjøen G, Line P-D, Naper C, Reisæter AV, Åsberg A. Five decades with grandparent donors: The Norwegian strategy and experience. *Ped Transplant* 2020; 24: e13751.
- 255: Kramer A, Boenink R, Noordzij M, Bosdriesz JR, Stel VS, Beltrán P, Ruiz JC, Seyahi N, Comas Farnés J, Stendahl M, Garneata L, Winzeler R, Golan E, František L, Korejwo G, Bonthuis M, Lassalle M, Slon Roblero MF, Kuzema V, Hommel K, Stojceva-Taneva O, Åsberg A, Kramar R, Hemmeler MH, De Meester J, Vazelov E, Andrushev A, Castro de la Nuez P, Helve J, Komissarov K, Casula A, Magaz A, Santiuste de Pablos C, Bubić I, Traynor JP, Ioannou K, Idrizi A, Pálsson R, des Grottes J-M, Spustova V, Tolaj-Avidiu M, Jarraya F, Nordio M, Ziginiskiene E, Massy Z, Jäger KJ. The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) registry Annual report 2017: a summary. *Clin Kidney J* 2020; 13(4): 693-709.
- 254: Chandra A, Svensson M, Åsberg A, Schmidt EB, Bjerve KS, Jenssen T, Hartmann A, Ueland T, Eide IA. Trans fatty acids and survival in renal transplantation. *J Ren Nutr* 2019; 29(3): 169-180.
- 253: Lorent M, Foucher Y, Kerleau C, Brouard S, Baayen C, Lebouter S, Naesens M, Bestard Matamoros O, Åsberg A, Giral M. The EKITE network (Epidemiology in Kidney Transplantation - a European validated database): an initiative epidemiological and translational European collaborative research. *BMC Nephrology* 2019; 20(1): 365.
- 252: Heldal K, Midtvedt K, Lønning K, Iversen T, Hernæs KH, Tsarpali V, Reisæter AV, Bernklev T. Kidney transplantation: an attractive and cost-effective alternative for older patients? A cost-utility study. *Clin Kidney J*. 2019; 12(6): 888-894

- 251: Antlanger M, Noordzij M, van de Luijngaarden M, Carrero JJ, Palsson R, Finne P, Hemmelder MH, Aresté-Fosalba N, Reisæter AV, Cases A, Traynor JP, Kramar R, Massy Z, Jager KJ, Hecking M; ERA-EDTA Registry. Sex Differences in Kidney Replacement Therapy Initiation and Maintenance. *Clin J Am Soc Nephrol*. 2019; 14(11): 1616-1625.
- 250: Hruskova Z, Pippias M, Stel VS, Abad-Díez JM, Benítez Sánchez M, Caskey FJ, Collart F, De Meester J, Finne P, Heaf JG, Magaz A, Palsson R, Reisæter AV, Salama AD, Segelmark M, Traynor JP, Massy ZA, Jager KJ, Tesar V. Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry. *Am J Kidney Dis*. 2019; 73(2): 184-193.
- 249: Kramer A, Pippias M, Noordzij M, Stel VS, Andrushev AM, Aparicio-Madre MI, Arribas Monzón FE, Åsberg A, Barbullushi M, Beltrán P, Bonthuis M, Caskey FJ, Castro del la Nuez P, Cernevski H, De Meester J, Finne P, Golan E, Heaf JG, Hemmelder MH, Ioannou K, Kantaria N, Komissarov K, Korejwo G, Kramar R, Lassalle M, Lopot F, Macário F, Mackinnon B, Pálsson R, Pechter U, Piñera VC, Santiuste de Pablos C, Segarra-Medrano A, Seyahi N, Slon Roblero MF, Stojceva-Taneva O, Vazellov E, Winzeler R, Ziginiskiene E, Massy Z, Jäger KJ. The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) registry Annual report 2016: a summary. *Clin Kidney J* 2019; 12(5): 702-720.
- 248: Stel VS, Awadhpersad R, Pippias M, Ferrer-Alamar M, Finne P, Fraser SD, Heaf JG, Hemmelder MH, Martínez-Castelao A, de Meester J, Palsson R, Prischl FC, Segelmark M, Traynor JP, Santamaria R, Reisaeter AV, Massy ZA, Jager KJ. International comparison of trends in patients commencing renal replacement therapy by primary renal disease. *Nephrology (Carlton)*. 2019; 24(10): 1064-1076.
- 247: Tantiyavarong P, Kramer A, Heaf JG, Finne P, Åsberg A, Cases A, Caskey F, Massy ZA, Jäger KJ, Noordzij M. Changes in clinical indicators related to the transition from dialysis to kidney transplantation – data from the ERA-EDTA Registry. *Clin Kidney J* 2019; 13(2): 188-198.
- 246: Thorsen IS, Bleskestad IH, Åsberg A, Hartmann A, Skadeberg Ø, Brede C, Ueland T, Pasch A, Reisæter AV, Gøransson LG. Vitamin D as a risk factor for patient survival after kidney transplantation; a prospective observational cohort study. *Clin Transplant* 2019; e13517.
- 245: Gustavsen MT, Midtvedt K, Lønning K, Jacobsen T, Reisæter AV, De Geest S, Andersen MH, Hartmann A, Åsberg A. Evaluation of tools for annual capture of adherence to immunosuppressive medications after renal transplantation. *Transplant Int* 2019; 32(6): 614-625.
- 244: Egeland EJ, Reisæter AV, Robertsen I, Midtvedt K, Strøm EH, Holdaas H, Hartmann A, Åsberg A. High tacrolimus clearance - a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study. *Transplant Int* 2019; 32(3): 257-269.

- 243: Nordheim E, Birkeland K, Åsberg A, Hartmann A, Horeland R, Jenssen T. Preserved insulin secretion and kidney function in recipients with functional pancreas grafts 1 year after transplantation: a single-center prospective observational study. *Eur J Endocrinol* 2018; 179(4): 251-259.
- 242: Bjørneklett R, Solbakken V, Bostad L, Fismen AS. Exploring sex-specific differences in the presentation and outcomes of ANCA-associated vasculitis: a nationwide registry-based cohort study. *Int Urol Nephrol* 2018; 50(7): 1311-1318.
- 241: Bjørneklett R, Solbakken V, Bostad L, Fismen AS. Prognostic Factors in Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis with Severe Glomerular Sclerosis: A National Registry-Based Cohort Study. *Patholog Res Int* 2018: 5653612.
- 240: Bjørneklett R, Bostad L, Fismen AS. Prognosis and Histological Classification in Elderly Patients with ANCA-Glomerulonephritis: A Registry-Based Cohort Study. *Biomed Res Int* 2018: 7581567.
- 239: Solbakken V, Fismen AS, Bostad L, Bjørneklett R. Impact of Proteinase 3 versus Myeloperoxidase Positivity on Risk of End-Stage Renal Disease in ANCA-Associated Glomerulonephritis Stratified by Histological Classification: A Population-Based Cohort Study. *Dis Markers* 2018: 3251517.
- 238: Weiner M, Bjørneklett R, Hrušková Z, Mackinnon B, Poulton CJ, Sindelar L, Mohammad AJ, Eriksson P, Gesualdo L, Geetha D, Crnogorac M, Jayne D, Hogan SL, Geddes C, Tesar V, Aasarød K, Segelmark M. Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. *Nephrol Dial Transplant* 2018; 34(2): 301-308.
- 237: Hemke AC, Heemskerk MBA, van Diepen M, Kramer A, de Meester J, Heaf JG, Abad Diez JM, Torres Guinea M, Finne P, Brunet P, Vikse BE, Caskey FJ, Traynor JP, Massy ZA, Couchoud C, Groothoff JW, Nordio M, Jager KJ, Dekker FW, Hoitsma AJ. Performance of an easy-to-use prediction model for renal patient survival: an external validation study using data from the ERA-EDTA Registry. *Nephrol Dial Transplant* 2018; 33(10): 1786-1793.
- 236: Ruggajo P, Leh S, Svarstad E, Marti HP, Vikse BE. Low birth weight associates with glomerular area in young male IgA nephropathy patients. *BMC Nephrol.* 2018; 19(1): 287.
- 235: Kramer A, Pippias M, Noordzij M, Stel VS, Afentakis N, Ambühl PM, Andrushev AM, Arcos FE, Arribas MFE, Åsberg A, Barbullushi M, Bonthuis M, Caskey FJ, Castro de la Nuez P, Cernevskis H, des Grottes J-M, Garneata L, Golan E, Hemmeler MH, Ioannou K, Jarraya F, Kolesnyk M, Komissarov K, Lassalle M, Macario F, Mahillo-Duran B, Martín de Francisco AL, Palsson R, Pechter L, Resic H, Rutkowski B, Santiuste de Pablos C, Seyahi N, Simic OS, Slon RMF, Spustova V, Stojceva-Taneva O, Traynor J, Massy Z, Jager KJ. The European Renal Association – European Dialysis

and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary. *Clin Kidney J* 2018; 11(1): 108-122.

- 234: Foss S, Nordheim E, Sørensen DW, Syversen TB, Midtvedt K, Åsberg A, Dahl T, Bakkan PA, Foss AE, Geiran O, Fiane AE, Line PD. First Scandinavian protocol for controlled donation after circulatory death using normo-thermic regional perfusion. *Transplantation Direct* 2018; 4(7): e366.
- 233: Skaare H, Svensson M, Jenssen T, Åsberg A, Schmidt EB, Chandra A, Ueland T, Michelsen A, Mollnes TE, Hartmann A, Eide IA. Plasma n-6 polyunsaturated fatty acid level and survival in renal transplantation. *J Ren Nutr* 2018; 28(5): 333-339.
- 232: Pippias M, Jäger KJ, Åsberg A, Berger S, Finne P, Heaf J, Lempinen M, Magaz A, Massy Z, Stel V. Young deceased donor kidneys show a survival benefit over older donor kidneys in transplant recipients aged 20-50 years. A study by the ERA-EDTA Registry. *Nephrol Dial Transpl* 2018; doi: 10.1093/ndt/gfy268.
- 231: Ocak G, Noordzij M, Rookmaaker MB, Cases A, Couchoud C, Heaf JG, Jarraya F, De Meester J, Groothoff JW, Waldum-Grevbo BE, Palsson R, Resic H, Remón C, Finne P, Stendahl M, Verhaar MC, Massy ZA, Dekker FW, Jager KJ. Mortality due to bleeding, myocardial infarction and stroke in dialysis patients. *J Thromb Haemost.* 2018; 16(10): 1953-1963.
- 230: Lindahl P, Horneland R, Nordheim E, Hartmann A, Aandahl EM, Grzyb K, Haugaa H, Kjøsén G, Åsberg A, Jenssen T. Outcomes in Pancreas Transplantation Alone versus Simultaneous Pancreas and Kidney Transplantation with Exocrine Drainage through a Duodenoduodenostomy. *Am J Transplant* 2018; 18(1): 154-162.
- 229: Lønning K, Midtvedt K, Bernklev T, Brunborg C, Andersen MH, von der Lippe N, Reisaeter AV, Line PD, Hartmann A, Heldal K. Changes in health related quality of life in older candidates waiting for kidney transplantation. *Nephrology (Carlton)* 2018; 23(10): 948-956.
- 228: Svarstad E, Leh S, Skrunes R, Kampevoll Larsen K, Eikrem Ø, Tøndel C. Bedside Stereomicroscopy of Fabry Kidney Biopsies: An Easily Available Method for Diagnosis and Assessment of Sphingolipid Deposits. *Nephron* 2018; 138(1): 13-21.
- 227: Pippias M, Jager KJ, Caskey F, Casula A, Erlandsson H, Finne P, Heaf J, Heinze G, Hoitsma A, Kramar R, Lempinen M, Magaz A, Midtvedt K, Mumford LL, Pascual J, Prütz KG, Sørensen SS, Traynor JP, Massy ZA, Ravanan R, Stel VS. Kidney transplant outcomes from older deceased donors: a paired kidney analysis by the European Renal Association-European Dialysis and Transplant Association Registry. *Transpl Int* 2018; 31(7): 708-719.
- 226: Lønning K, Heldal K, Bernklev T, Brunborg C, Andersen MH, von der Lippe N, Reisaeter AV, Line PD, Hartmann A, Midtvedt K. Improved Health-Related Quality of Life in Older Kidney Recipients 1 Year After Transplantation. *Transplant Direct* 2018; 4(4): e351.

- 225: Hruskova Z, Pippias M, Stel VS, Abad-Díez JM, Benítez Sánchez M, Caskey FJ, Collart F, De Meester J, Finne P, Heaf JG, Magaz A, Palsson R, Reisæter AV, Salama AD, Segelmark M, Traynor JP, Massy ZA, Jager KJ, Tesar V. Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry. *Am J Kidney Dis.* 2018; S0272-6386(18): 30768-6.
- 224: Majak GB, Reisæter AV, Weedon-Fekjær H, Henriksen T, Michelsen TM. The Effect of Pregnancy on the Long-term Risk of Graft Loss, Cardiovascular Disease, and Death in Kidney Transplanted Women in Norway: A Retrospective Cohort Study. *Transplantation.* 2018; 102(9): e391-e396.
- 223: Pippias M, Stel VS, Kramer A, Abad Diez JM, Aresté-Fosalba N, Ayav C, Buturovic J, Caskey FJ, Collart F, Couchoud C, De Meester J, Heaf JG, Helanterä I, Hemmeler MH, Kostopoulou M, Noordzij M, Pascual J, Palsson R, Reisaeter AV, Traynor JP, Massy Z, Jager KJ. Access to kidney transplantation in European adults aged 75-84 years and related outcomes: an analysis of the European Renal Association-European Dialysis and Transplant Association Registry. *Transpl Int.* 2018; 31(5): 540-553.
- 222: Ceretta ML, Noordzij M, Luxardo R, De Meester J, Abad Diez JM, Finne P, Heaf JG, Couchoud C, Kramer R, Collart F, Cases A, Palsson R, Reisæter AV, Rydell H, Massy ZA, Jager KJ, Kramer A. Changes in co-morbidity pattern in patients starting renal replacement therapy in Europe-data from the ERA-EDTA Registry. *Nephrol Dial Transplant.* 2018; 33(10): 1794-1804.
- 221: Gagnum V, Saeed M, Stene LC, Leivestad T, Joner G, Skrivarhaug T. Low Incidence of End-Stage Renal Disease in Childhood-Onset Type 1 Diabetes Followed for Up to 42 Years. *Diabetes Care.* 2018; 41(3): 420-425.
- 220: Bjørneklett R, Solbakken V, Bostad L, Fismen AS. Exploring sex-specific differences in the presentation and outcomes of ANCA-associated vasculitis: a nationwide registry-based cohort study. *Int Urol Nephrol* 2018; 50(7): 1311-1318.
- 219: Skrunes R, Tøndel C, Leh S, Larsen KK, Houge G, Davidsen ES, Hollak C, van Kuilenburg ABP, Vaz FM, Svarstad E. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease. *Clin J Am Soc Nephrol* 2017; 12(9): 1470-1479
- 218: .Skrunes R, Svarstad E, Kampevold Larsen K, Leh S, Tøndel C. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. *Nephrol Dial Transplant* 2017; 32(5): 807-813
- 217: Smedbråten J, Sagedal S, Åsberg A, Hartmann A, Rollag H, Mjøen G, Fagerland MW, Hansen SWK, Mollnes TE, Thiel S. Collectin Liver 1 and Collectin Kidney 1 of the lectin complement pathway are associated with mortality after kidney transplantation. *Am J Transplant* 2017; 17(1): 265-271.
- 216: Pippias M, Kramer A, Noordzij M, Alonso de la Torre R, Ambühl PM, Aparicio MMI, Arribas Monzón F, Åsberg A, Bonthuis M, Bouzas Caamaño E, Bubic I, Caskey FJ, Castro de la Nuez P, Cernevskis H, de los Ángeles GBM, des Grottes J-M, Fernández

- GR, Ferrer-Alamar M, Finne P, Garneata L, Golan E, Heaf JG, Hemmeler MH, Idrizi A, Ioannou K, Jarraya F, Kantaria N, Kolesnyk M, Kramar R, Lassalle M, Lezaic VV, Lopot F, Macario F, Magaz A, Martín de Francisco AL, Martín EE, Martínez Castela A, Metcalfe W, Moreno Alia I, Nordio M, Ots-Rosenberg M, Palsson R, Ratkovic M, Resic H, Rutkowski B, Santiuste de Pablos C, Seyahi N, Slon Roblero MF, Spustova V, Stas Koenraad JF, Stendahl Mara E, Stojceva-Taneva O, Vazelov E, Ziginiskiene E, Massy Z, Jager KJ, and Stel Vianda S. The European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2014: A summary. *Clin Kidney J* 2017; 10(2): 154-169.
- 215: Eide IA, Halden TAS, Hartmann A, Åsberg A, Dahle DO, Jenssen TG. Associations between posttransplantation diabetes mellitus and renal graft survival. *Transplantation* 2017; 101(6): 1282-1289.
- 214: Midtvedt K, Bergan S, Reisæter AV, Vikse BE, Åsberg A. Exposure to mycophenolate and fatherhood. *Transplantation* 2017; 101(7); e214-e217.
- 213: Dupont L, Eide IA, Hartmann A, Christensen JH, Åsberg A, Jenssen T, Krarupm H, Svensson M. Haptoglobin 2-2 genotype, patient and graft survival in renal transplant recipients. *Progress in Transplantation* 2017; 27(4): 386-391.
- 212: Gagnum V, Stene LC, Leivestad T, Joner G, Skrivarhaug T. Long-term Mortality and End-Stage Renal Disease in a Type 1 Diabetes Population Diagnosed at Age 15-29 Years in Norway. *Diabetes Care* 2017; 40(1): 38-45
- 211: Dahle DO, Grotmol T, Leivestad T, Hartmann A, Midtvedt K, Reisæter AV, Mjøen G, Pihlstrøm HK, Næss H, Holdaas H. Association Between Pretransplant Cancer and Survival in Kidney Transplant Recipients. *Transplantation* 2017; 101(10): 2599-2605
- 210: Heldal K, Hartmann A, Lønning K, Leivestad T, Reisæter AV, Line PD, Holdaas H, Midtvedt K. Should patients older than 65 years be offered a second kidney transplant? *BMC Nephrol* 2017; 18(1): 13
- 209: Vidal E, van Stralen KJ, Chesnaye NC, Bonthuis M, Holmberg C, Zurowska A, Trivelli A, Da Silva JEE, Herthelius M, Adams B, Bjerre A, Jankauskiene A, Miteva P, Emirova K, Bayazit AK, Mache CJ, Sánchez-Moreno A, Harambat J, Groothoff JW, Jager KJ, Schaefer F, Verrina E; ESPN/ERA-EDTA Registry. Infants Requiring Maintenance Dialysis: Outcomes of Hemodialysis and Peritoneal Dialysis. *Am J Kidney Dis* 2017; 69(5): 617-625
- 208: Koefoed-Nielsen P, Weinreich I, Bengtsson M, Lauronen J, Naper C, Gäbel M, Sørensen SS, Wennberg L, Reisaeter AV, Møller BK; Nordic Kidney group and the Tissue Typing group in Scandiatransplant. Scandiatransplant acceptable mismatch program (STAMP) a bridge to transplanting highly immunized patients. *HLA* 2017; 90(1): 17-24
- 207: Majak GB, Reisæter AV, Zucknick M, Lorentzen B, Vangen S, Henriksen T, Michelsen TM. Preeclampsia in kidney transplanted women; Outcomes and a simple prognostic risk score system. *PLoS One* 2017; 12(3): e0173420

- 206: van den Brand JAJG, Pippias M, Stel VS, Caskey FJ, Collart F, Finne P, Heaf J, Jais JP, Kramar R, Massy ZA, De Meester J, Traynor JP, Reisæter AV, Wetzels JFM, Jager KJ. Lifetime risk of renal replacement therapy in Europe: a population-based study using data from the ERA-EDTA Registry. *Nephrol Dial Transplant* 2017; 32(2): 348-355
- 205: Norby GE, Mjøen G, Bjørneklett R, Vikse BE, Holdaas H, Svarstad E, Aasarød K. Outcome in biopsy-proven Lupus nephritis: Evaluation of biopsies from the Norwegian Kidney Biopsy Registry. *Lupus* 2017; 26(8): 881-885
- 204: van den Brand JAJG, Pippias M, Stel VS, Caskey FJ, Collart F, Finne P, Heaf J, Jais JP, Kramar R, Massy ZA, De Meester J, Traynor JP, Reisæter AV, Wetzels JFM, Jager KJ. Lifetime risk of renal replacement therapy in Europe: a population-based study using data from the ERA-EDTA Registry. *Nephrol Dial Transplant* 2017; 32(2): 348-355
- 203: Chesnaye NC, Schaefer F, Bonthuis M, Holman R, Baiko S, Baskın E, Bjerre A, Cloarec S, Cornelissen EAM, Espinosa L, Heaf J, Stone R, Shtiza D, Zagozdzon I, Harambat J, Jager 202: KJ, Groothoff JW, van Stralen KJ; ESPN/ERA-EDTA Registry Committee. Mortality risk disparities in children receiving chronic renal replacement therapy for the treatment of end-stage renal disease across Europe: an ESPN-ERA/EDTA registry analysis. *Lancet* 2017; 389(10084): 2128-2137
- 201: Lindahl JP, Massey RJ, Hartmann A, Aakhus S, Endresen K, Günther A, Midtvedt K, Holdaas H, Leivestad T, Horneland R, Øyen O, Jenssen T. Cardiac Assessment of Patients With Type 1 Diabetes Median 10 Years After Successful Simultaneous Pancreas and Kidney Transplantation Compared With Living Donor Kidney Transplantation. *Transplantation* 2017; 101(6): 1261-1267
- 200: Knoop T, Vikse BE, Mwakimonga A, Leh S, Bjørneklett R. Long-term outcome in 145 patients with assumed benign IgA nephropathy. *Nephrol Dial Transplant* 2017; 32(1): 1841-1850.
- 199: García-Carro C, Dörje C, Åsberg A, Midtvedt K, Reinholt FP, Strøm EH, Holdaas H, Serón D, Reisæter AV. Inflammation in early kidney allograft surveillance biopsies and its relationship with de novo donor specific antibodies. *Transplantation* 2017; 101(6): 1410-1415.
- 198: Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Størset E, Gustavsen MT, Reisæter AV, Klaasen R, Bergan S, Holdaas H, Hartmann A, Åsberg A. High tacrolimus clearance is a risk factor for acute rejection in the early phase after renal transplantation. *Transplantation* 2017; 101(8): e273-e279.
- 197: Torres IB, Reisæter AV, Moreso F, Åsberg A, Vidal M, Garcia-Carro C, Midtvedt K, Reinholt FP, Scott H, Castella E, Salcedo M, Dörje C, Sellares J, Azancot MA, Perello M, Holdaas H, Seron D. Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants. *Transplant Int* 2017; 30(11): 1119-1131.

- 196: Rizvi SMH, Aagnes B, Holdaas H, Gude E, Boberg KM, Bjørtuft Ø, Helsing P, Leivestad T, Møller B, Gjersvik P. Long-term Change in the Risk of Skin Cancer After Organ Transplantation: A Population-Based Nationwide Cohort Study. *JAMA Dermatol.* 2017; 153(12): 1270-1277.
- 195: Sriskandarajah S, Bostad L, Myklebust TÅ, Møller B, Skrede S, Bjørneklett R. Cancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study. *Int J Nephrol* 2017; 6013038.
- 194: Paunas TIF, Finne K, Leh S, Marti HP, Mollnes TE, Berven F, Vikse BE. Glomerular abundance of complement proteins characterized by proteomic analysis of laser-captured microdissected glomeruli associates with progressive disease in IgA nephropathy. *Clin Proteomics.* 2017; 14: 30.
- 193: Vidal E, van Stralen KJ, Chesnaye NC, Bonthuis M, Holmberg C, Zurowska A, Trivelli A, Eduardo Esteves Da Silva J, Herthelius M, Adams B, Bjerre A, Jankauskiene A, Miteva P, Emirova K, Bayazit AK, Mache JC, Sánchez-Moreno A, Harambat J, Groothoff JW, Jager KJ, Schaefer F, Verrina E. Infants requiring maintenance dialysis: outcomes of hemodialysis and peritoneal dialysis. *Am J Kidney Dis.* 2017; 69; 617-625
- 192: Rizvi SMH, Aagnes B, Holdaas H, Gude E, Boberg KM, Bjørtuft Ø, Helsing P, Leivestad T, Møller B, Gjersvik P. Long-term change in the risk of skin cancer after organ transplantation. A population-based nationwide cohort study. *JAMA Dermatol.* Published online October 18, 2017; 153(12): 1270-1277.
- 191: Dahle DO, Grotmol T, Leivestad T, Hartmann A, Midtvedt K, Reisæter AV, Mjøen G, Pihlstrøm HK, Næss H, Holdaas H. Association between pretransplant cancer and survival in kidney transplant recipients. *Transplantation* 2017; 101; 2599–2605.
- 190: Majak GB, Reisæter AV, Zucknick M, Lorentzen B, Vangen S, Henriksen T, Michelsen TM. Preeclampsia in kidney transplanted women; Outcomes and a simple prognostic risk score system *PLoS One* 2017; 12; e0173420
- 189: Heldal K, Hartmann A, Lønning K, Leivestad T, Reisæter AV, Line PD, Holdaas H, Midtvedt K. Should patients older than 65 years be offered a second kidney transplant? *BMC Nephrol.* 2017; 18; 13
- 188: Eide IA, Halden TAS, Hartmann A, Dahle DO, Åsberg A, Jenssen T. Associations between posttransplantation diabetes mellitus and renal graft survival. *Transplantation* 2017, 101: 1282–1289
- 187: Brand JAJGvd, Pippias M, Stel VS, Caskey FJ, Collart F, Finne P, Heaf J, Jais J-P, Kramar R, Massy ZA, Meester JD, Traynor JP, Reisæter AV, Wetzels JFM, Jager KJ. Lifetime risk of renal replacement therapy in Europe: a population-based study using data from the ERA-EDTA Registry. *Nephrol. Dial. Transplant.* 2017, 32: 348-355.
- 186: Chesnaye NC, Schaefer F, Bonthuis M, Holman R, Baiko S, Baskin E, Bjerre A, Cloarec S, Cornelissen EAM, Espinosa L, Heaf JG, Stone R, Shtiza D, Zagozdzon I, Harambat J, Jager KJ, Groothoff JW, van Stralen KJ. Mortality risk disparities in children receiving chronic renal replacement therapy for the treatment of end-stage renal disease across Europe. An ESPN/ERA-EDTA Registry analysis. *Lancet* 2017; 389; 2128-2137.

- 185: Pesce F, Diciolla M, Binetti G, Naso D, Ostuni VC, Di Noia T, Vågane AM, Bjørneklett R, Suzuki H, Tomino Y, Di Sciascio E, Schena FP. Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients. *Nephrol Dial Transplant*. 2016; 31(1): 80-6
- 184: Bjørneklett R, Sriskandarajah S, Bostad L. Prognostic Value of Histologic Classification of ANCA-Associated Glomerulonephritis. *Clin J Am Soc Nephrol*. 2016; 11(12): 2159-2167
- 183: von der Lippe N, Waldum-Grevbo B, Varberg Reisæter A, Os I. Is HRQOL in dialysis associated with patient survival or graft function after kidney transplantation? *BMC Nephrol*. 2016; 17: 94
- 182: Mjøen G, Reisaeter A, Hallan S, Line PD, Hartmann A, Midtvedt K, Foss A, Dahle DO, Holdaas H. Overall and cardiovascular mortality in Norwegian kidney donors compared to the background population. *Nephrol Dial Transplant*. 2016; 31(1): 170
- 181: Mjøen G, Reisaeter AV, Dahle DO. HLA Mismatch and Allograft Survival. *Transplantation*. 2016; 100(9): e52
- 180: Lofaro D, Jager KJ, Abu-Hanna A, Groothoff JW, Arikoski P, Hoecker B, Roussey-Kesler G, Spasojević B, Verrina E, Schaefer F, van Stralen KJ; ESPN/ERA-EDTA Registry. Identification of subgroups by risk of graft failure after paediatric renal transplantation: application of survival tree models on the ESPN/ERA-EDTA Registry. *Nephrol Dial Transplant*. 2016; 31(2): 317-24
- 179: Krischock LA, van Stralen KJ, Verrina E, Tizard EJ, Bonthuis M, Reusz G, Hussain FK, Jankauskiene A, Novljan G, Spasojević-Dimitrijeva B, Podracka L, Zaller V, Jager KJ, Schaefer F; ESPN/ERA-EDTA Registry. Anemia in children following renal transplantation-results from the ESPN/ERA-EDTA Registry. *Pediatr Nephrol*. 2016; 31(2): 325-33
- 178: Tjaden LA, Noordzij M, van Stralen KJ, Kuehni CE, Raes A, Cornelissen EA, O'Brien C, Papachristou F, Schaefer F, Groothoff JW, Jager KJ; ESPN/ERA-EDTA Registry Study Group. Racial Disparities in Access to and Outcomes of Kidney Transplantation in Children, Adolescents, and Young Adults: Results From the ESPN/ERA-EDTA (European Society of Pediatric Nephrology/European Renal Association-European Dialysis and Transplant Association) Registry. *Am J Kidney Dis*. 2016; 67(2): 293-301
- 177: Hogan J, Couchoud C, Bonthuis M, Groothoff JW, Jager KJ, Schaefer F, Van Stralen KJ; ESPN/ERA-EDTA Registry. Gender Disparities in Access to Pediatric Renal Transplantation in Europe: Data From the ESPN/ERA-EDTA Registry. *Am J Transplant*. 2016; 16(7): 2097-105
- 176: Mekahli D, van Stralen KJ, Bonthuis M, Jager KJ, Balat A, Benetti E, Godefroid N, Edvardsson VO, Heaf JG, Jankauskiene A, Kerecuk L, Marinova S, Puteo F, Seeman T, Zurowska A, Pirenne J, Schaefer F, Groothoff JW; ESPN/ERA-EDTA Registry. Kidney Versus Combined Kidney and Liver Transplantation in Young People With Autosomal Recessive Polycystic Kidney Disease: Data From the European Society for

- Pediatric Nephrology/European Renal Association-European Dialysis and Transplant (ESPN/ERA-EDTA) Registry. *Am J Kidney Dis.* 2016; 68(5): 782-788
- 175: Smedbråten J, Mjøen G, Hartmann A, Åsberg A, Rollag H, Mollnes TE, Sandvik L, Fagerland MW, Thiel S, Sagedal S. Low level of MAp44, an inhibitor of the lectin complement pathway, and long-term graft and patient survival; a cohort study of 382 kidney recipients. *BMC Nephrology* 2016; 17(1): 148.
- 174: Størset E, Åsberg A, Hartmann A, Reisæter AV, Holdaas H, Skauby M, Bergan S, Midtvedt M. Low-target tacrolimus in de novo standard risk renal transplant recipients - a single-center experience. *Nephrology* 2016; 21(10): 821-827.
- 173: Dahle DO, Åsberg A, Hartmann A, Holdaas H, Bachtler M, Jenssen TG, Dionisi M, Pasch A. *Serum calcification propensity is a strong and independent determinant of cardiac and all-cause mortality in kidney transplant recipients.* *Am J Transplant* 2016; 16(1): 204-212.
- 172: Hölttä T, Bonthuis M, Van Stralen KJ, Bjerre A, Topaloglu R, Ozaltin F, Holmberg C, Harambat J, Jager KJ, Schaefer F, Groothoff JW. Timing of renal replacement therapy does not influence survival and growth in children with congenital nephrotic syndrome caused by mutations in NPHS1: data from the ESPN/ERA-EDTA Registry. *Pediatr Nephrol.* 2016; 31:2317-2325
- 171: Koopman JJ, Kramer A, van Heemst D, Åsberg A, Beuscart JB, Buturović-Ponikvar J, Collart F, Couchoud CG, Finne P, Heaf JG, Massy ZA, De Meester JM, Palsson R, Steenkamp R, Traynor JP, Jager KJ, Putter H. Measuring senescence rates of patients with end-stage renal disease while accounting for population heterogeneity: an analysis of data from the ERA-EDTA Registry. *Ann Epidemiol.* 2016; 26:773-779
- 170: van Huis M, Bonthuis M, Sahpazova E, Mencarelli F, Spasojević B, Reusz G, Caldas-Afonso A, Bjerre A, Baiko S, Vondrak K, Molchanova EA, Kolvek G, Zaikova N, Böhm M, Ariceta G, Jager KJ, Schaefer F, van Stralen KJ, Groothoff JW. Considerable variations in growth hormone policy and prescription in paediatric end-stage renal disease across European countries-a report from the ESPN/ERA-EDTA registry. *Nephrol Dial Transplant.* 2016; 31:609-619
- 169: Lindahl JP, Massey RJ, Hartmann A, Aakhus S, Endresen K, Günther A, Midtvedt K, Holdaas H, Leivestad T, Horneland R, Øyen O, Jenssen T. Cardiac assessment of patients with type 1 diabetes median 10 years after successful simultaneous pancreas and kidney transplantation compared with living donor kidney transplantation. *Transplantation* 2016; 101: 1261–1267
- 168: Eide IA, Halden TA, Hartmann A, Åsberg A, Dahle DO, Reisaeter AV, Jenssen T. Mortality risk in post-transplantation diabetes mellitus based on glucose and HbA1c diagnostic criteria *Transpl Int* 2016, 29, 568-78
- 167: Lønning K, Midtvedt K, Leivestad T, Reisæter AV, Line PD, Hartmann A, Heldal K. Are Octogenarians With End-Stage Renal Disease Candidates for Renal Transplantation? *Transplantation* 2016, 100, 2705-2709
- 166: Majak GB, Sandven I, Lorentzen B, Vangen S, Reisaeter AV, Henriksen T, Michelsen TM. Pregnancy outcomes following maternal kidney transplantation: a national cohort study *Acta Obstet Gynecol Scand* 2016, 95, 1153-61

- 165: Skrunes R, Svarstad E, Reisæter AV, Marti HP, Vikse BE. End Stage Renal Disease Predicts Increased Risk of Death in First Degree Relatives in the Norwegian Population. *PLoS One*, 11 (11), e0165026
- 164: Kramer A, Pippias M, Stel V, . . . Reisæter AV, . . . Jager KJ, Noordzij M. Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus. *Clin Kidney J*, 2016, 9: 457-469
- 163: Pippias M, Jager KJ, Kramer A, Leivestad T, Sánchez MB, Caskey FJ, Collart F, Couchoud C, Dekker FW, Finne P, Fouque D, Heaf JG, Hemmeler MH, Kramar R, Meester JD, Noordzij M, Palsson R, Pascual J, Zurriaga O, Wanner C, Stel VS. The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA Registry. *Nephrol. Dial. Transplant.* 2016 31: 831-841
- 162: Eide IA, Dahle DO, Svensson M, Hartmann A, Åsberg A, Bjerne KS, Christensen JH, Schmidt EB, Lauritsen ME, Lund K, Jenssen T. Plasma levels of marine n-3 fatty acids and cardiovascular risk markers in renal transplant recipients. *Eur J Clin Nutr.* 2016; 70: 824-830.
- 161: Ruggajo P, Skrunes R, Svarstad E, Skjærven R, Reisæter AV, Vikse BE. Familial Factors, Low Birth Weight, and Development of ESRD: A Nationwide Registry Study. *Am J Kidney Dis.* 2016; 67: 601-8
- 160: Pippias M, Stel VS, Aresté-Fosalba N, Couchoud C, Fernandez-Fresnedo G, Finne P, Heaf JG, Hoitsma A, De Meester J, Pálsson R, Ravani P, Segelmark M, Traynor JP, Reisæter AV, Caskey FJ, Jager KJ. Long-term Kidney Transplant Outcomes in Primary Glomerulonephritis: Analysis From the ERA-EDTA Registry. *Transplantation* 2016;100:1955-62
- 159: Ruggajo P, Svarstad E, Leh S, Marti HP, Reisæter AV, Vikse BE. Low Birth Weight and Risk of Progression to End Stage Renal Disease in IgA Nephropathy--A Retrospective Registry-Based Cohort Study. *PloS ONE.* 2016;11(4):e0153819.
- 158: Luijtgarden MWMvd, Jager KJ, Segelmark M, Pascua J, Collart F, Hemke AC, Remón C, Metcalfe W, Miguel A, Kramar R, Aasarød K, Hanna AA, Krediet RT, Schön S, Ravani P, Caskey FJ, Couchoud C, Palsson R, Wanner C, Finne P, Noordzij M. Trends in dialysis modality choice and related patient survival in the ERA-EDTA Registry over a 20-year period. *Nephrol Dial Transplant* 2016; 31: 120–128
- 157: Eide IA, Jenssen T, Hartmann A, Diep LN, Dahle DO, Reisæter AV, Bjerne KS, Christensen JH, Schmidt EB, Svensson M. Plasma levels of marine n-3 polyunsaturated fatty acids and renal allograft survival. *Nephrol Dial Transplant* 2016; 31: 160–167
- 156: LindahlJP, Hartmann A, Aakhus S, Endresen K, Midtvedt K, Holdaas H, Leivestad T, Horneland R, Øyen O, Jenssen T. Long-term cardiovascular outcomes in type 1 diabetic patients after simultaneous pancreas and kidney transplantation compared with living donor kidney transplantation. *Diabetologia* 2016; 59: 844-52.
- 155: Eide IA, Jenssen T, Hartmann A, Diep LN, Dahle DO, Reisæter AV, Bjerne KS, Christensen JH, Schmidt EB, Svensson M. The association between marine n-3 polyunsaturated fatty acid levels and survival after renal transplantation. *Clin J Am Soc Nephrol* 2015; 10: 1246-56

154. Pesce F, Diciolla M, Binetti G, Naso D, Ostuni VC, Di Noia T, Vågane AM, Bjørneklett R, Suzuki H, Tomino Y, Di Sciascio E, Schena FP. Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients. *Nephrol Dial Transplant*. 2016; 31(1): 80-6.
- 153: Smedbråten YV, Sagedal A, Mjøen G, Hartmann A, Fagerland M, Rollag H, Mollnes TE, Thiel S. High Ficolin-3 level at the time of transplantation is an independent risk factor for graft loss in kidney transplant recipients. *Transplantation* 2015; 99; 791-796.
- 152: Hruskova Z, Stel VS, Jayne D, Aasarød K, De Meester J, Ekstrand A, Eller K, Heaf JG, Hoitsma A, Martos Jiménez C, Ravani P, Wanner C, Tesar V, Jager KJ. Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association-European Dialysis and Transplant Association Registry. *Am J Kidney Dis*. 2015; 66: 613-20.
- 151: Knoop T, Vagane AM, Vikse BE, Svarstad E, Magnusdottir BT, Leh S, et al. Addition of eGFR and Age Improves the Prognostic Absolute Renal Risk-Model in 1,134 Norwegian Patients with IgA Nephropathy. *American Journal of Nephrology*. 2015: 41; 210-9.
- 150: Morken NH; Diaz-Garcia C; Reisaeter AV; Foss A; Leivestad T; Geiran O; Hervas D; Brannstrom M. Obstetric and neonatal outcome of pregnancies fathered by males on immunosuppression after solid organ transplantation. *Am. J. Transpl*. 2015: 15;1666-73.
- 149: Waldum-Grevbo B, Leivestad T, Reisaeter AV, Os I. Impact of initial dialysis modality on mortality: a propensity-matched study. *BMC Nephrology* 2015: 16;179 – published online 30.Oct.2015
- 148: Breckenridge K, Bekker HL, Gibbons E, vd Veer SN, Abbott D, Briançon S, Cullen R, Garneata L, Jager KJ, Lønning K, Metcalfe W, Morton RL, Murtagh FEM, Prutz K, Robertson S, Rychlik I, Schon S, Sharp L, Speyer E, Tentori F, Caskey FJ. How to routinely collect data on patient-reported outcome and experience measures in renal registries in Europe: an expert consensus meeting. *Nephrol Dial Transplant* 2015; 30: 1605–1614
- 147: Dahle DO, Eide IA, Åsberg A, Leivestad T, Holdaas H, Jenssen TG, Fagerland MW, Pihlstrøm H, Mjøen G, Hartmann A. Aortic stiffness in a mortality risk calculator for kidney transplant recipients. *Transplantation* 2015; 99: 1730-7.
- 146: Pippias M, Stel V, . . . Leivestad T, . . . Jager KJ. Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry annual report. *Clin Kidney J* 2015; 8: 248-261
- 145: Sandvik LF, Skarstein K, Krynitz B, Volchenkov R, Sviland L, Leivestad T, Jonsson R, Appel S. Peritumoral dermis of squamous cell carcinomas in renal transplant recipients contains less CD11c+ myeloid dendritic cells and FoxP3+ T cells compared to immunocompetent controls. *J Eur Acad Dermatol Venereol*. 2015; 29:2128-35.
- 144: Sriskandarajah S, Aasarød K, Skrede S, Knoop T, Reisaeter AV, Bjørneklett R. Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies. *Nephrol Dial Transplant* 2015: 30: i67–i75

- 143: Norum J, Leivestad T, Eriksen BO, Skår S, Fagerheim A, Reisæter AV. Regional differences in renal replacement therapy in northern Norway 2000-2012. *Int J Circumpolar Health* 2015, 74:24298
- 142: Vogelzang JL, van Stralen KJ, Noordzij M, Abad Diez J, Carrero JJ, Couchoud C, Dekker FW, Finne P, Fouque D, Heaf JG, Hoitsma A, Leivestad T, de Meester J, Metcalfe W, Palsson R, Postorino M, Ravani P, Vanholder R, Wallner M, Wanner C, Groothoff JW, Jager KJ. Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. *Nephrol Dial Transplant* 2015; 30: 1028–1037
- 141: Skrunes R, Svarstad E, Reisæter AV, Vikse BE. Familial Clustering of ESRD in the Norwegian Population. *Clin J Am Soc Nephrol* 2014; 9, 1692-1700
- 140: von der Lippe N, Waldum B, Østhus TB, Reisæter AV, Os I. Health related quality of life in patients in dialysis after renal graft loss and effect of gender. *BMC Womens Health*, 2014; 14: 34
- 141: Wühl E, van Stralen KJ, Wanner C, Ariceta G, Heaf JG, Bjerre AK, Palsson R, Duneau G, Hoitsma AJ, Ravani P, Schaefer F, Jager KJ. Renal replacement therapy for rare diseases affecting the kidney: an analysis of the ERA-EDTA Registry. *Nephrol Dial Transplant*. 2014; 29 Suppl 4:iv1-iv8.
- 140: Chesnaye N, Bonthuis M, Schaefer F, Groothoff JW, Verrina E, Heaf JG, Jankauskiene A, Lukosiene V, Molchanova EA, Mota C, Peco-Antiæ A, Ratsch IM, Bjerre A, Roussinov DL, Sukalo A, Topaloglu R, Van Hoeck K, Zagozdzon I, Jager KJ, Van Stralen KJ; on behalf of the ESPN/ERA–EDTA registry. Demographics of paediatric renal replacement therapy in Europe: a report of the ESPN/ERA-EDTA registry. *Pediatr Nephrol*. 2014 Jul 21
- 139: Noordzij M, Jager KJ, van der Veer SN, Kramar R, Collart F, Heaf JG, Stojceva-Taneva O, Leivestad T, Buturovic-Ponikvar J, Sánchez MB, Moreso F, Prütz KG, Severn A, Wanner C, Vanholder R, Ravani P. Use of vascular access for haemodialysis in Europe; a report from the ERA-EDTA registry. *Nephrol Dial Transplant* 2014; 29: 1956-1964
- 138: Bleskestad IH, Bergrem H, Leivestad T, Hartmann A, Gøransson LG. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. *Clin Transplant* 2014; 28: 479–486
- 137: Dahle DO, Jenssen T, Holdaas H, Leivestad T, Vårdal M, Mjøen G, Reisæter AV, Toft I, Hartmann A. Uric acid has a J-shaped association with cardiovascular and all-cause mortality in kidney transplant recipients. *Clin Transplant* 2014; 28: 134–140
- 136: Lægreid IK, Aasarød K, Bye A, Leivestad T, Jordhøy M. The impact of nutritional status, physical function, comorbidity and early versus late start in dialysis on quality of life in older dialysis patients. *Ren Fail* 2014; 36 (1), 9-16
- 135: Smedbråten YV, Sagedal S, Leivestad T, Mjøen G, Osnes K, Rollag H, Reisæter AV, Foss A, Os I, Hartmann A. The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival. *Clin Transplant* 2014; 28: 120-6
- 134: Sandvik LF, Skarstein K, Sviland L, Svarstad E, Nilsen AE, Leivestad T, Jonsson R, Appel S. CD11c+ dendritic cells rather than Langerhans cells are reduced in normal

- skin of immunosuppressed renal transplant recipients. *Acta Derm Venereol.* 2014;94:173-8
- 133: Harambat J, Bonthuis M, van Stralen KJ, Ariceta G, Battelino N, Bjerre A, Jahnukainen T, Leroy V, Reusz G, Sandes AR, Sinha MD, Groothoff JW, Combe C, Jager KJ, Verrina E, Schaefer F, for the ESPN/ERA-EDTA Registry. Adult Height in Patients with Advanced CKD Requiring Renal Replacement Therapy during Childhood. *Clin J Am Soc Nephrol* 2014; 9: 92-9.
- 132: Noordzij M, Kramer A, . . . Leivestad T, . . . Jager KJ. Renal replacement therapy in Europe – a summary of the 2011 ERA-EDTA Registry annual report. *Clin Kidney J* 2014; 7: 227-238
- 131: Mjøen G, Hallan S, Hartmann A, Foss A, Midtvedt K, Øyen O, Reisæter A, Pfeffer P, Jenssen T, Leivestad T, Line P-D, Øvrehus M, Dale DO, Pihlstrøm H, Holme I, Dekker FW, Holdaas H. Long-term risks for kidney donors. *Kidney International* 2014; 86:162-7
- 130: Andresen PA, Nymoene DA, Kjærheim K, Leivestad T, Helsing P. Susceptibility to cutaneous squamous cell carcinoma in renal transplant recipients associates with genes regulating melanogenesis independent of their role in pigmentation. *Biomarkers in Cancer* 2013;5; 41-47
- 129 Schroijen MA, Luijtgarden MWMvd, Noordzij M, Ravani P, Jarraya F, Collart F, Prütz KG, Fogarty DG, Leivestad T, Prischl FC, Wanner C, Dekker FW, Jager KJ, Dekkers OM. Survival in dialysis patients is different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition. *Diabetologia.* 2013;56:1949-57.
- 128: Dörje C, Midtvedt K, Holdaas H, Naper C, Strøm EH, Øyen O, Leivestad T, Aronsen T, Jenssen T, Flaa-Johnsen L, Lindahl JP, Hartmann A, Reisæter AV. Early versus late acute antibody-mediated rejection in renal transplant recipients. *Transplantation.* 2013;96:79-84.
- 127: Knoop T, Vikse BE, Svarstad E, Leh S, Reisæter AV, Bjørneklett R. Mortality in patients with IgA nephropathy. *Am J Kidney Dis.* 2013; 62: 883-90
- 126: Dahle DO, Midtvedt K, Hartmann A, Jenssen T, Holdaas H, Mjøen G, Leivestad T, Asberg A. Endothelial dysfunction is associated with graft loss in renal transplant recipients. *Transplantation.* 2013;95:733-9
- 125: Heldal K, Thorarinsdottir S, Hartmann A, Leivestad T, Reisæter AV, Foss AE, Midtvedt K. Induction with interleukin-2 antagonist for transplantation of kidneys from older deceased donors: an observational study. *Transplant Res.* 2013; 2:11.
- 124: Lindahl JP, Hartmann A, Horneland R, Holdaas H, Reisæter AV, Midtvedt K, Leivestad T, Øyen O, Jenssen T. Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease. *Diabetologia* 2013 56(6):1364-71.
- 123: Kramer A, Stel VS, . . . Leivestad T, . . . Jager KJ. Renal replacement therapy in Europe – a summary of the 2010 ERA-EDTA Registry annual report. *Clin Kidney J* 2013;6:105-115

- 122: Åsberg A, Apeland T, Reisæter AV, Foss A, Leivestad T, Heldal K, Thorud LO, Eriksen BO, Hartmann A, on behalf of the NILS study group. Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation – results from an aborted trial. *Clin Transplant*. 2013; 27(2): E151-6.
- 121: van Stralen KJ, Verrina E, Belingheri M, Dudley J, Dusek J, Grenda R, Macher MA, Puretic Z, Rubic J, Rudaitis S, Rudin C, Schaefer F, Jager KJ; ESPN/ERA-EDTA Registry. (*among named collaborators: Bjerre A, Leivestad T*) Impact of graft loss among kidney diseases with a high risk of post-transplant recurrence in the paediatric population. *Nephrol Dial Transplant*. 2013; 28(4):1031-8.
- 120: Vikse BE, Irgens LM, Karumanchi SA, Thadhani R, Reisæter AV, Skjærven R. Familial factors in the association between preeclampsia and later ESRD. *Clin J Am Soc Nephrol*. 2012;7(11):1819-26.
- 119: van Stralen KJ, Krischock L, Schaefer F, Verrina E, Groothoff JW, Evans J, Heaf J, Ivanov D, Kostic M, Maringhini S, Podracká L, Printza N, Pundziene B, Reusz GS, Vondrak K, Jager KJ, Tizard EJ; ESPN/ERA-EDTA Registry. (*among named collaborators: Leivestad T, Brackman D*). Prevalence and predictors of the sub-target Hb level in children on dialysis. *Nephrol Dial Transplant*. 2012 ;27(10):3950-7.
- 118: Temme J, Kramer A, Jager KJ, Lange K, Peters F, Müller GA, Kramar R, Heaf JG, Finne P, Palsson R, Reisæter AV, Hoitsma AJ, Metcalfe W, Postorino M, Zurriaga O, Santos JP, Ravani P, Jarraya F, Verrina E, Dekker FW, Gross O. Outcomes of male patients with Alport syndrome undergoing renal replacement therapy. *Clin J Am Soc Nephrol*. 2012;7(12):1969-76.
- 117: Kramer A, Stel VS, Geskus RB, Tizard EJ, Verrina E, Schaefer F, Heaf JG, Kramar R, Krischock L, Leivestad T, Palsson R, Ravani P, Jager KJ. The effect of timing of the first kidney transplantation on survival in children initiating renal replacement therapy. *Nephrol Dial Transplant*. 2012; 27(3):1256-64.
- 116: Wühl E, van Stralen KJ, Verrina E, Bjerre A, Wanner C, Heaf JG, Zurriaga O, Hoitsma A, Niaudet P, Palsson R, Ravani P, Jager KJ, Schaefer F. Timing and outcome of renal replacement therapy in patients with congenital malformations of the kidney and urinary tract. *Clin J Am Soc Nephrol*. 2013;1: 67-74.
- 115: Osthus TB, von der Lippe N, Ribu L, Rustøen T, Leivestad T, Dammen T, Os I. Health-related quality of life and all-cause mortality in patients with diabetes on dialysis. *BMC Nephrol*. 2012;13(1):78.
- 114 Skauby MH, Øyen O, Hartman A, Leivestad T, Wadström J. Kidney transplantation with and without simultaneous bilateral native nephrectomy in patients with polycystic kidney disease: a comparative retrospective study. *Transplantation*. 2012;94(4):383-8.
- 113: Osthus TB, Preljevic VT, Sandvik L, Leivestad T, Nordhus IH, Dammen T, Os I. Mortality and health-related quality of life in prevalent dialysis patients: Comparison between 12-items and 36-items short-form health survey. *Health Qual Life Outcomes*. 2012;10:46.
- 112: Ocak G, van Stralen KJ, Rosendaal FR, Verduijn M, Ravani P, Palsson R, Leivestad T, Hoitsma AJ, Ferrer-Alamar M, Finne P, De Meester J, Wanner C, Dekker FW, Jager

- KJ. Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients. *J Thromb Haemost.* 2012;10(12):2484-2493.
- 111: Harambat J, van Stralen KJ, Espinosa L, Groothoff JW, Hulton SA, Cerkauskiene R, Schaefer F, Verrina E, Jager KJ, Cochat P; European Society for Pediatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry. (*among collaborators: Leivestad T*). Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. *Clin J Am Soc Nephrol.* 2012;7(3):458-65.
- 110: Valderhaug TG, Hjelmessaeth J, Jenssen T, Roislien J, Leivestad T, Hartmann A. Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses. *Transplantation* 2012; 94(7): 714-20.
- 109: Sandvik LF, Vogelsang P, Leivestad T, Jonsson R, Appel S. Quantification of Plasmacytoid Dendritic Cells and Type 1 Myeloid Dendritic Cells in Peripheral Blood of Renal Transplant Recipients With and Without Squamous Cell Carcinoma. *Acta Derm Venereol.* 2012;92(6):623-4
- 108: Mjøen G, Reisæter A, Hallan S, Line PD, Hartmann A, Midtvedt K, Foss A, Dahle DO, Holdaas H. Overall and cardiovascular mortality in Norwegian kidney donors compared to the background population. *Nephrol Dial Transplant* 2012;27(1):443-7.
- 107: Stel VS, Kramar R, Leivestad T, Hoitsma AJ, Metcalfe W, Smits JM, Ravani P, Jager KJ. Time trend in access to the waiting list and renal transplantation: a comparison of four European countries *Nephrol Dial Transplant* 2012; 27: 3621-31.
- 106: Reisæter AV, Foss A, Hartmann A, Leivestad T, Midtvedt K. The Kidney Transplantation Program in Norway since 2000 In: Terasaki PI, Cecka JM (eds). *Clinical Transplants 2011*. Terasaki Foundation Laboratory, Los Angeles; pp. 111-118.
- 105: Bjørneklett R, Vikse BE, Bostad L, Leivestad T, Iversen BM. Long term risk of ESDR in IgAN; validation of Japanese prognostic modell in a Norwegian cohort. *Nephrol Dial Transplant* 2012; 27 (4): 1485-91.
- 104: Bleskestad IH, Bergrem H, Leivestad T, Gøransson LG. Intact parathyroid hormone levels in renal transplant patients with normal transplant function. *Clin Transplant.* 2011;25: E566-70.
- 103: Carrero JJ, de Jager DJ, Verduijn M, Ravani P, De Meester J, Heaf JG, Finne P, Hoitsma AJ, Pascual J, Jarraya F, Reisaeter AV, Collart F, Dekker FW, Jager KJ. Cardiovascular and noncardiovascular mortality among men and women starting dialysis. *Clin J Am Soc Nephrol.* 2011; 6: 1722-1730.
- 102: Heldal K, Hartmann A, Leivestad T, Lien B, Foss AE, Midtvedt K. Nyretransplantasjon er et alternativ for pasienter over 70 år. *Tidsskr Nor Legeforen* 2011; 131: 2004-07.
- 101: Luijngaarden MWMvd, Noordzij M, Stel VS, Ravani P, Jarraya F, Collart F, Schön S, Leivestad T, Puttinger H, Wanner C, Jager KJ. Effects of comorbid and demographic factors on dialysis modality choice and related patient survival in Europe. *Nephrol Dial Transplant* 2011; 26: 2940-47.
- 100: Mjøen G, Stavem K, Westlie L, Midtvedt K, Fauchald P, Norby G, Holdaas H. Quality of life in kidney donors. *Am J Transplant.* 2011; 11(6): 1315-19.

- 99: Myhre HA, Dorenberg DH, Kristiansen KI, Rollag H, Leivestad T, Åsberg A, Hartmann A. Incidence and outcome of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. *Transplantation* 2011; 92(2):, 217- 223.
- 98: Norby GE, Leivestad T, Mjøen G, Hartmann A, Midtvedt K, Gran JT, Holdaas H. Premature cardiovascular disease in patients with systemic lupus erythematosus influences survival after renal transplantation. *Arthritis Rheum.* 2011;63(3):733-37.
- 97: Bjørneklett R, Vikse BE, Smerud HK, Bostad L, Leivestad T, Hartmann A, Iversen BM. Pre-transplant course and risk of kidney transplant failure in IgA nephropathy patients. *Clin Transplant* 2011; 25: E356-E365.
- 96: Valderhaug TG, Hjelvesæth J, Hartmann A, Røislien J, Bergrem HA, Leivestad T, Line PD, Jenssen T. The association of early post-transplant glucose levels. with long-term mortality. *Diabetologia* 2011; 54: 1341-49.
- 95: Heldal K, Hartmann A, Leivestad T, Foss A, Midtvedt K. Risk variables associated with the outcome of kidney recipients >70 years of age in the new millennium. *Nephrol Dial Transplant* 2011; 26: 2706-11.
- 94: Aasebø W, Midtvedt K, Valderhaug TG, Leivestad T, Hartmann A, Reisæter AV, Jenssen T, Holdaas H. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab. *Nephrol Dial Transplant* 2010; 25: 1289-1293
- 93: Heldal K, Hartmann A, Grootendorst DC, Jager DJ de, Leivestad T, Foss A, Midtvedt K. Benefit of kidney transplantation beyond 70 years of age. *Nephrol Dial Transplant* 2010; 25: 1680-1687.
- 92: Vikse BE, Hallan S, Bostad L, Leivestad T, Iversen BM. Previous preeclampsia and risk for progression of biopsy-verified kidney disease to end-stage renal disease. *Nephrol Dial Transplant* 2010; 25: 3289-3296.
- 91: Sandvik MK, Iversen BM, Irgens LM, Skjaerven R, Leivestad T, Søfteland E, Vikse BE. Are adverse pregnancy outcomes risk factors for development of end-stage renal disease in women with diabetes? *Nephrol Dial Transplant* 2010; 25: 3600-3607.
- 90: Bergrem HA, Gretland Valderhaug T, Hartmann A, Hjelvesæth J, Leivestad T, Bergrem H, Jenssen T. Undiagnosed Diabetes in Kidney Transplant Candidates: A Case-Finding Strategy. *Clin J Am Soc Nephrol* 2010 5(4): 616-22
- 89: Gude E, Andreassen AK, Arora S, Gullestad L, Grov I, Hartmann A, Leivestad T, Fiane AE, Geiran OR, Vardal M, Simonsen S. Acute renal failure early after heart transplantation: risk factors and clinical consequences. *Clin Transplant* 2010; 24 (6): E207-E213
- 88: Norby GE, Strøm EH, Midtvedt K, Hartmann A, Gilboe IM, Leivestad T, Stenstrøm J, Holdaas H. Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study. *Ann Rheum Dis.* 2010;69: 1484-1487.
- 87: Couchoud C, Kooman J, Finne P, Leivestad T, Stojceva-Taneva O, Ponikvar JB, Collart F, Kramar R, de Francisco A, Kitty J. Jager KJ, on behalf of the QUEST working group on dialysis adequacy. From registry data collection to international comparisons: examples of haemodialysis duration and frequency. *Nephrol Dial Transplant* 2009; 24: 217-224

- 86: Couchoud C, Jager KJ, Tomson C, Cabanne JF, Collart F, Finne P, de Francisco A, Frimat L, Garneata L, Leivestad T, Lemaitre V, Limido A, Ots M, Resic H, Stojceva-Taneva O, Kooman J, on behalf of the QUEST working group on dialysis adequacy. Assessment of urea removal in haemodialysis and the impact of the European best practice guidelines. *Nephrol Dial Transplant* 2009; 24: 1267-1274
- 85: Heldal K, Hartmann A, Leivestad T, Svendsen MV, Foss A, Lien B, Midtvedt K. Clinical outcomes in elderly kidney transplant recipients are related to acute rejection episodes rather than pretransplant comorbidity. *Transplantation* 2009; 87: 1045-1051
- 84: Kramer A, Stel V, Zoccali C, Heaf J, Ansell D, Gronhagen-Riska C, Leivestad T, Simpson K, Palsson R, Postorino M, Jager K. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. *Nephrol Dial Transplant* 2009; 24: 3557-3566
- 83: Foss A, Heldal K, Scott H, Foss S, Leivestad T, Jørgensen PF, Scholz T, Midtvedt K. Kidneys from deceased donors more than 75 years perform acceptably after transplantation. *Transplantation* 2009; 87: 1437-1441.
- 82: Witzak BJ, Leivestad T, Line PD, Holdaas H, Reisaeter AV, Jenssen TG, Midtvedt K, Bitter J, Hartmann A. Experience from an active preemptive kidney transplantation program--809 cases revisited. *Transplantation* 2009; 88: 672-677.
- 81: Vikse BE, Irgens LM, Leivestad T, Hallan S, Iversen BM. Low birth weight increases risk for end-stage renal disease. *J Am Soc Nephrol* 2008; 19: 151-157
- 80: Heldal K, Leivestad T, Hartmann A, Svendsen MV, Lien BH, Midtvedt K. Kidney transplantation in the elderly – the Norwegian experience. *Nephrol Dial Transplant* 2008; 23: 1026-1031
- 79: Tangeraas T, Bjerre A, Lien B, Kyte A, Monn E, Cvancarova M, Leivestad T, Reisaeter AV. Long-term outcome of pediatric renal transplantation: The Norwegian experience in three eras 1970-2006. *Pediatr Transplantation* 2008; 12: 762-768
- 78: Vikse BE, Irgens LM, Leivestad T, Skjærven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. *N Engl J Med* 2008; 359: 800-809
- 77: van Manen JG, van Dijk PCW, Stel VS, Dekker FW, Clèries M, Conte F, Feest TG, Kramar R, Leivestad T, Briggs JD, Stengel B, Jager KJ. Confounding effect of co-morbidity in survival studies in patients on renal replacement therapy. *Nephrol Dial Transplant*. 2007; 22: 187-195.
- 76: Øien CM, Reisaeter AV, Leivestad T, Dekker FW, Line PD, Os I. Living donor kidney transplantation: The effects of donor age and gender on short- and long-term outcomes. *Transplantation* 2007; 83: 600-606.
- 75: Valderhaug TG, Hjelmesaeth J, Rollag H, Leivestad T, Roislien J, Jenssen T, Hartmann A. Reduced Incidence of New-Onset Posttransplantation Diabetes Mellitus During the Last Decade. *Transplantation* 2007; 84: 1125-1130.
- 74: Hjelmesaeth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M, Jenssen T. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. *Kidney Int* 2006; 69: 588-595.

- 73: Leivestad T. Behandling av kronisk nyresvikt i Norge – utvikling gjennom de siste 25 år. *LNT-Nytt* 2006; 2: 26-28.
- 72: Hjelmæsæth J, Ueland T, Flyvbjerg A, Bollerslev J, Leivestad T, Jenssen T, Krarup Hansen T, Thiel S, Sagedal S, Røislien J, Hartmann A. Early Posttransplant Serum Osteoprotegerin Levels Predict Long-Term (8-Year) Patient Survival and Cardiovascular Death in Renal Transplant Patients. *J. Am. Soc. Nephrol.* 2006;17:1746-1754.
- 71: Yoshino M, Kuhlmann MK, Kotanko P, Greenwood RN, Pisoni RL, Port FK, Jager KJ, Homel P, Augustijn H, de Charro FT, Collart F, Ereik E, Finne P, Garcia-Garcia G, Grönhagen-Riska C, Ioannidis GA, Ivis F, Leivestad T, Løkkegaard F, Lopot F, Jin D-C, Kramar R, Nakao T, Nandakumar M, Ramirez S, van der Sande FM, Schön S, Simpson K, Walker RG, Zaluska W, Levin NW. International Differences in Dialysis Mortality Reflect Background General Population Atherosclerotic Cardiovascular Mortality. *J Am Soc Nephrol* 2006;17: 3510-3519.
- 70: Stewart JH, McCredie MRE, Williams SM, Jager KJ, Trpeski L, McDonald SP, Fenton SS, van Dijk PCW, Finne P, Schön S, Leivestad T, Løkkegaard H, Billiouw J-M, Kramar R, Magaz A, Vela E, Garcia-Blasco MJ, Ioannidis GA, Lim YN. The enigma of hypertensive ESRD: Observations on incidence and trends in 18 European, Canadian, and Asian-Pacific populations, 1998 to 2002. *Am J Kidney Dis* 2006; 48: 183-191
- 69: Flesland Ø, Leivestad T, Solheim BG. Survival of renal allografts from living donors and the importance of being the mother of the organ donor. *Transfusion and Apheresis Science* 2005; 32: 13-15.
- 68: Øien CM, Reisæter AV, Leivestad T, Pfeffer P, Fauchald P, Os I. Gender imbalance among donors in living kidney transplantation: the Norwegian experience. *Nephrol Dial Transplant.* 2005; 20: 783-9.
- 67: Stel V.S., P.C.W. van Dijk, J.G. van Manen, F.W. Dekker, F. Conte, D. Ansell, R. Kramar, T. Leivestad, E. Vela, J. D. Briggs, K.J. Jager. Prevalence of co-morbidity in different European RRT populations and its effect on access to renal transplantation. *Nephrol Dial Transplant.* 2005; 20: 2803-11.
- 66: Foss A, Tuvin D, Leivestad T, Øyen O, Bentsdal Ø. Should kidneys from older cadaveric donors be age-matched to the recipient? *Transplant Proc* 2005; 37: 3280-2.
- 65: Sagedal S, Hartmann A, Nordal KP, Foss A, Degré M, Leivestad T, Osnes K, Fauchald P, Rollag H. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. *Kidney Int* 2004;66:329-337
- 64: E. Thorsby, P. Pfeffer, T. Leivestad. Role of HLA molecules in the induction of alloimmune responses: Clinical significance in the cyclosporine era. *Transplant Proc* 2004; 36(Suppl 2S):16-21.
- 63: D. Albrechtsen, T. Leivestad, P. Fauchald, P. Pfeffer on behalf of the Oslo Kidney Transplant Group. Experience with cyclosporine in 1519 kidney transplantations from living donors in a national transplant programme 1983-2002. *Transplant Proc* 2004; 36(Suppl 2S):89-93.

- 62: Midtvedt K, Fauchald P, Lien B, Hartmann A, Albrechtsen D, Bjerkely B.L, Leivestad T, Brekke I.B. Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection. *Clin Transplant* 2003; 17: 69-74.
- 61: Westlie L, Leivestad T, Holdaas H, Lien B, Meyer K, Fauchald P. Hvordan går det med dem som donerer en nyre til transplantasjon? *Tidsskr Nor Lægeforen* 2003; 123: 1060-1062.
- 60: Westlie L, Leivestad T, Holdaas H, Lien B, Hartmann A, Fauchald P. Er dagens praksis ved bruk av levende giver ved nyretransplantasjon akseptabel? *Tidsskr Nor Lægeforen* 2003; 123: 1063-1065.
- 59: Witczak B, Hartmann A, Leivestad T, Øyen O, Svennevig J. Cardiovascular surgery in renal failure patients with or without subsequent renal transplantation. *Transplant Proc* 2003; 35: 798-800.
- 58: Jakobsen A, Holdaas H, Leivestad T. Ethics and safety of living kidney donation. *Transplant Proc* 2003; 35: 1177-1178.
- 57: Westlie L, Leivestad T, Holdaas H, Lien B, Meyer K, Fauchald P. Report from the Norwegian National Hospitals Living Donor Registry: one-year data, January 1, 2002. *Transplant Proc* 2003;35:777-778.
- 56: Midtvedt K, Fauchald P, Bergan S, Høiegggen A, Hallan S, Svarstad E, Bergrem H, Eriksen BO, Pfeffer PF, Dalen I, Leivestad T. C₂ monitoring in maintenance renal transplant recipients: Is it worthwhile? *Transplantation* 2003;76:1236-1238.
- 55: Sagedal S, Nordal KP, Hartmann A, Sund S, Scott H, Degré M, Foss A, Leivestad T, Fauchald P, Rollag H. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. *Am J Transpl* 2002; 2: 850-856.
- 54: Bergrem H, Leivestad T. Diabetic nephropathy and end-stage renal failure: The Norwegian story. *Adv Ren Replace Ther* 2001; 8: 4-12.
- 53: Fauchald P, Leivestad T. Nyretransplantasjon ved diabetisk nyresvikt. *Diabetes for helsepersonell* 2001; 1: 4-6.
- 52: Dijk PCWv, Jager KJ, Charro Fd, Collart F, Cornet R, Dekker FW, Grönhagen-Riska C, Kramar R, Leivestad T, Simpson K, Briggs JD. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. *Nephrol Dial Transplant* 2001; 16: 1120-1129.
- 51: Leivestad T. Norsk Nefrologiregister fra 1980 til 2000. *LNT-Nytt* 2001; 5: 10-11.
- 50: Katre S, Leivestad T, Fauchald P. Aktiv uremibehandling ved autosomal dominant polycystisk nyresykdom. *Tidsskr Nor Lægeforen* 2000; 120: 1015-1019.
- 49: Gjersvik P, Hansen S, Møller B, Leivestad T, Geiran O, Simonsen S, Pfeffer P, Fauchald P. Are heart transplant recipients more likely to develop skin cancer than kidney transplant recipients? *Transpl Int* 2000; 13 (suppl 1): 380-381
- 48: Sagedal S, Nordal KP, Hartmann A, Degré M, Holter E, Foss A, Osnes K, Leivestad T, Fauchald P, Rollag H. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. *Transplantation* 2000; 70: 1166-1174.

- 47: Hartmann A, Leivestad T. Behandling av pasienter med kronisk diabetisk nyresvikt. *Diabetes for helsepersonell* 2000; 3: 14-17
- 46: Paulsen D, Kløw NE, Rogstad B, Leivestad T, Lien B, Vatne K, Fauchald P. Preservation of renal function by percutaneous transluminal angioplasty in ischemic renal disease. *Nephrol Dial Transplant* 1999; 14: 1454-1461
- 45: Jensen P, Hansen S, Møller B, Leivestad T, Pfeffer P, Geiran O, Fauchald P, Simonsen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. *J Am Acad Dermatol* 1999; 49: 177-186
- 44: Jakobsen A, Leivestad T, Foss A. The use of unrelated living renal donors and the «cross-over» debate. In: Malacrida R, Martinoli S, Thiel G, Wullschleger R (eds). *Donazioni e trapianti d'organo. I trapianti dai vivi (The Living Donors)*. Edizioni Alice, CH-6949 Comano; pp 53-57, 1999.
- 43: Bentsdal ØH, Leivestad T, Fauchald P, Albrechtsen D, Pfeffer P, Lien B, Foss A, Øyen O, Hartmann A, Nordal K, Sødal G, Flatmark A, Thorsby E, Brekke IB. The national kidney transplant program in Norway still results in unchanged waiting lists. In: Terasaki PI, Cecka JM (eds). *Clinical Transplants 1998*. UCLA Tissue Typing Laboratory, Los Angeles; pp. 221-228, 1999.
- 42: Leivestad T, Reisæter AV, Brekke IB, Vartdal F, Thorsby E. The role of HLA matching in renal transplantation: experience from one center. *Rev Immunogenetics* 1999;1: 343-350.
- 41: Jensen P, Hansen S, Møller B, Leivestad T, Pfeffer P, Fauchald P. Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone? *Transplant Proc* 1999; 31: 1120
- 40: Leivestad T. Norsk Nefrologiregister. 25 år med datainnsamling. In: Westlie L (ed). *Norsk nyremedisin. Et moderne eventyr*. Norsk nyremedisinsk forening, Fredrikstad; pp. 104-111, 1999.
- 39: Reisæter AV, Leivestad T, Vartdal F, Spurkland A, Fauchald P, Brekke IB, Thorsby E. A strong impact of matching for a limited number of HLA-DR antigens on graft survival and rejection episodes. A single center study of first cadaveric kidneys to non-sensitized recipients. *Transplantation* 1998; 66: 523-528
- 38: Foss A, Leivestad T, Brekke IB, Fauchald P, Bentsdal Ø, Lien B, Pfeffer P, Sødal G, Albrechtsen D, Søreide O, Flatmark A. Unrelated living donors in 141 kidney transplantations. A one-center study. *Transplantation* 1998; 66: 49-52
- 37: Bergan S, Rugstad HE, Bentsdal Ø, Sødal G, Hartmann A, Leivestad T, Stokke O. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. *Transplantation* 1998; 66: 334-339
- 36: Reisæter AV, Leivestad T, Fauchald P, Brekke I, Thorsby E. Influence of matching for HLA-DR in first cadaveric renal transplantation in nonsensitized recipients. *Transplant Proc* 1997; 29: 3099-3100.
- 35: Pfeffer PF, Leivestad T, Albrechtsen D, Fauchald P, Brekke IB. Anamnestic cancer: How long should the cancer-free interval be before renal transplantation? *Transplant Proc* 1997; 29: 3163.

- 34: Hjelmesæth J, Hartmann A, Kofstad J, Stenstrøm J, Leivestad T, Egeland T, Fauchald P. Glucose intolerance following renal transplantation depends upon prednisolone dose and recipient age. *Transplantation* 1997; 64: 979-983
- 33: Midtvedt K, Tafjord AB, Hartmann A, Nordal KP, Holdaas H, Sødal G, Leivestad T, Fauchald P. Half dose of OKT3 is efficient in treatment of steroid resistant renal allograft rejection. *Transplantation* 1996; 62: 38-42.
- 32: Brekke IB, Sødal G, Holdaas H, Fauchald P, Jervell J. Simultaneous pancreas and kidney transplantation. In: Mogensen CE (ed.): *The kidney and hypertension in diabetes mellitus*. 3. edition. Martinus Nijhoff Publishing, Boston; pp 513-520, 1996.
- 31: Jakobsen A, Albrechtsen D, Leivestad T. Renal transplantation - The Norwegian model. *Annals of Transplantation* 1996; 1: 32-35.
- 30: Leivestad T, Spurkland A, Knutsen I, Bratlie A, Vartdal F, Pfeffer P, Sødal G, Fauchald P, Thorsby E. Genomic HLA-DRB1 matching further improves clinical course after renal transplantation. *Transplant Proc* 1995; 27: 678-679.
- 29: Albrechtsen D, Leivestad T, Sødal G, Bentdal Ø, Berg KJ, Brekke I, Fauchald P, Flatmark A, Jakobsen A, Lien B, Nordal K, Pfeffer P, Thorsby E, Søreide O. Kidney transplantation in patients older than 70 years of age. *Transplant Proc* 1995; 27: 986-988
- 28: Reisaether AV, Leivestad T, Holdaas H, Hartmann A, Sødal G, Albrechtsen D, Flatmark A, Fauchald P. Pretransplant plasma exchange or immunoadsorption facilitates renal transplantation in immunized patients. *Transplantation* 1995; 60: 242-248.
- 27: Reisaether AV, Fauchald P, Leivestad T, Holdaas H, Hartmann A, Pfeffer P, Sødal G. Plasma exchange in highly sensitized patients as induction therapy after renal transplantation. *Transplant Proc* 1994; 26: 1758.
- 26: Fauchald P, Leivestad T, Rollag H, Albrechtsen D, Sødal G. The influence of cytomegalovirus antibody status on graft survival in renal transplantation. *Transplant Proc* 1994; 26, 1725
- 25: Leivestad T, Spurkland A, Bratlie A, Pfeffer P, Fauchald P, Sødal G, Thorsby E. Does genomic HLA-DR matching further enhance the effects of serological DR matching in clinical renal transplantation? *Transplant Proc* 1994; 26: 1748-1749.
- 24: Haugen G, Fauchald P, Sødal G, Leivestad T, Moe N. Pregnancy outcome in renal allograft recipients in Norway: The importance of immunosuppressive drug regimen and health status before pregnancy. *Acta Obstet Gynecol Scand* 1994; 73: 541-546.
- 23: Leivestad T, Thorsby E. Transplantationer. Betydningen av god HLA-forlikelighet. (The importance of HLA compatibility in organ transplantation). *Nord Med* 1994; 109: 188-190.
- 22: Leivestad T, Sødal G, Bratlie A, Albrechtsen D, Fauchald P, Pfeffer P, Vartdal F, Thorsby E. Role of HLA matching in cadaveric renal transplantation - influence of improved serological HLA-DR typing. *Transplant Proc* 1993; 25: 220-221.
- 21: Albrechtsen D, Leivestad T, Fauchald P, Flatmark A, Sødal G, Thorsby E. Results of the national kidney transplantation program in Norway. In: Terasaki PI, Cecka JM

- (eds). *Clinical Transplants 1992*. UCLA Tissue Typing Laboratory, Los Angeles; pp. 207-213 1993.
- 20: Pfeffer PF, Ohlman S, Jakobsen A, Fauchald P, Leivestad T, Tydén G, Flatmark A. A Scandinavian two-center study of BMA 031 in steroid-resistant rejection of renal grafts. *Transplantation* 1993; 56: 304-307.
 - 19: Westlie L, Fauchald P, Talseth T, Jakobsen A, Flatmark A. Quality of life in Norwegian kidney donors. *Nephrol Dial Transplant* 1993; 8: 1146-1150
 - 18: Hartmann A, Holdaas H, Fauchald P, Nordal KP, Berg KJ, Talseth T, Leivestad T, Brekke IB, Flatmark A. Fifteen years experience with renal transplantation in systemic amyloidosis. *Transplant Int* 1992; 5: 15-18.
 - 17: Gørlén T, Abdelnoor M, Enger E, Halvorsen S, Leivestad T, Malm OJ, Aarseth HP. Long term morbidity and mortality after kidney transplantation. *Scand J Urol Nephrol* 1992; 26: 397-401.
 - 16: Pfeffer PF, Jakobsen A, Albrechtsen D, Sødal G, Brekke I, Bentdal Ø, Leivestad T, Fauchald P, Flatmark A. BMA 031 effectively reverses steroid-resistant rejections in renal transplants. *Transplant Proc* 1991; 23: 1099-1100.
 - 15: Fauchald P, Sødal G, Albrechtsen D, Leivestad T, Berg KJ, Flatmark A. The use of elderly living donors in renal transplantation. *Transplant Int* 1991; 4: 51-53.
 - 14: Jakobsen A, Albrechtsen D, Fauchald P, Leivestad T, Sødal G, Flatmark A. Allowing relatives to bridge the gap: The Norwegian experience. In: Land W, Dossetor JB (eds). *Organ replacement therapy: Ethics, justice and commerce*. Springer-Verlag Berlin Heidelberg pp.48-49 1991.
 - 13: Fauchald P, Berg KJ, Brodwall EK, Talseth T, Flatmark A, Leivestad T, Halvorsen S. Behandling av kronisk nyresvikt med dialyse og transplantasjon. Utvikling, behov og organisering i Norge. (Renal replacement therapy in Norway - development, requirement and organization). *Tidsskr Nor Lægeforen* 1990; 110: 332-334.
 - 12: Leivestad T, Albrechtsen D, Bratlie A, Jakobsen A, Pfeffer P, Sødal G, Vartdal F, Flatmark A, Thorsby E. The role of HLA compatibility in renal transplantation from living donors. An analysis of 379 grafts. *Transplant Proc* 1990; 22: 153.
 - 11: Fauchald P, Leivestad T, Albrechtsen D, Willassen Y, Jakobsen A, Flatmark A. Plasma exchange and immunoadsorption prior to renal transplantation in allosensitized patients. *Transplant Proc* 1990; 22: 149-150.
 - 10: Albrechtsen D, Berg KJ, Brekke I, Fauchald P, Jakobsen A, Sødal G, Talseth T, Leivestad T, Flatmark A. Renal replacement therapy in the cyclosporine era: Results of a national transplantation program. *Transplant Proc* 1990; 22: 155-156.
 - 9: Albrechtsen D, Flatmark A, Leivestad T, Brynner H, Frødin L, Groth CG, Lundgren G, Persson N. Efficacy of cyclosporine in renal transplantation from HLA haploidentical living donors: No benefit of transfusion or additional azathioprine. *Transplant Proc* 1990; 22: 214-215.
 - 8: Jakobsen A, Albrechtsen D, Leivestad T, Sødal G, Talseth T, Flatmark A. Steroid resistant rejection: The effect of ATG on renal allograft survival. *Transplant Proc* 1990; 22: 225.

- 7: Albrechtsen D, Sødal G, Jakobsen A, Brekke I, Bentsdal Ø, Berg KJ, Fauchald P, Pfeffer P, Talseth T, Leivestad T, Flatmark A. Kidney transplantation from a spouse: An alternative to years of dialysis waiting for a graft that may never turn up? *Transplant Proc* 1990; 22: 1435.
- 6: Flesland Ø, Solheim BG, Gaustad P, Mellbye O, Albrechtsen D, Talseth T, Leivestad T. Antibody production by donor lymphocytes in transplant patients. *Transplantation* 1989; 48: 883-885.
- 5: Fauchald P, Albrechtsen D, Leivestad T, Pfeffer P, Talseth T, Flatmark A. Renal replacement therapy in patients over 60 years of age. *Transplant Proc* 1988; 20: 432-433.
- 4: Albrechtsen D, Fauchald P, Leivestad T, Talseth T, Flatmark A. Renal replacement therapy in elderly patients. *Transplant Proc* 1988; 20: 367-369.
- 3: Fauchald P, Albrechtsen D, Leivestad T, Berg KJ, Talseth T, Flatmark A. Renal replacement therapy in elderly patients. *Transplant Int* 1988; 1: 131-134.
- 2: Nordal KP, Dahl E, Albrechtsen D, Halse J, Leivestad T, Tretli S, Flatmark A. Aluminium accumulation and immunosuppressive effect in recipients of kidney transplants. *Brit Med J* 1988; 297: 1581-1582.
- 1: Fauchald P, Leivestad T, Bratlie A, Albrechtsen D, Talseth T, Flatmark A. Plasma exchange and immunosuppressive therapy before renal transplantation in allosensitized patients. *Transplant Proc* 1987; 19: 3748-3749.